The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Inhibition of Interleukin-1 by Anakinra Improves Vascular and Left Ventricular Function in Patients With Rheumatoid Arthritis
Abstract
Background—Interleukin-1 increases nitrooxidative stress. We investigated the effects of a human recombinant interleukin-1a receptor antagonist (anakinra) on nitrooxidative stress and vascular and left ventricular function. Methods and Results—In an acute, double-blind trial, 23 patients with rheumatoid arthritis were randomized to receive a single injection of anakinra (150 mg SC) or placebo and, after 48 hours, the alternative treatment. At baseline and 3 hours after the injection, we assessed (1) coronary flow reserve, aortic distensibility, systolic and diastolic (Em) velocity of the mitral annulus, and E to Em ratio (E/Em) using echocardiography; (2) flow-mediated, endothelium-dependent dilation of the brachial artery; and (3) malondialdehyde, nitrotyrosine, interleukin-6, endothelin-1, and C-reactive protein. In a chronic, nonrandomized trial, 23 patients received anakinra and 19 received prednisolone for 30 days, after which all indices were reassessed. Compared with baseline, there was a greater reduction in malondialdehyde, nitrotyrosine, interleukin-6, and endothelin-1 and a greater increase in flow-mediated dilation, coronary flow reserve, aortic distensibility, systolic velocity of mitral annulus, and E/Em after anakinra than after placebo (malondialdehyde −25% versus 9%; nitrotyrosine −38% versus −11%; interleukin-6 −29% versus 0.9%; endothelin-1 −36% versus −11%; flow-mediated dilation 45% versus −9%; coronary flow reserve 29% versus 4%; and aortic distensibility 45% versus 2%;P<0.05 for all comparisons). After 30 days of treatment, the improvement in biomarkers and in vascular and left ventricular function was greater in the anakinra group than in the prednisolone group (P<0.05). Conclusions—Interleukin-1 inhibition improves vascular and left ventricular function and is associated with reduction of nitrooxidative stress and endothelin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Nagueh, S. F., Middleton, K. J., Kopelen, H. A., Zoghbi, W. A., & Quiñones, M. A. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00344-6 · Cited by 3,029
McDonald's blood flow in arteries; theoretical, experimental and clinical principles
(1992) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(92)90079-y · Cited by 2,388
Interleukin-1 and interleukin-1 antagonism
Dinarello, C. (1991) · Blood · doi:10.1182/blood.v77.8.1627.1627 · Cited by 2,304
Kaur, H., & Halliwell, B. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00722-5 · Cited by 706
Hürlimann, D., Forster, A., Noll, G., Enseleit, F., Chenevard, R., Distler, O., Béchir, M., Spieker, L. E., Neidhart, M., Michel, B. A., et al. (2002) · Circulation · doi:10.1161/01.cir.0000037521.71373.44 · Cited by 574
IL-1 stimulates IL-6 production in endothelial cells.
Sironi, M., Breviario, F., Proserpio, P., Biondi, A., Vecchi, A., Van Damme, J., Dejana, E., & Mantovani, A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.2.549 · Cited by 521
Nitric Oxide Regulates Local Arterial Distensibility In Vivo
Wilkinson, I. B., Qasem, A., McEniery, C. M., Webb, D. J., Avolio, A. P., & Cockcroft, J. R. (2002) · Circulation · doi:10.1161/hc0202.101970 · Cited by 502
Mäki-Petäjä, K. M., Hall, F. C., Booth, A. D., Wallace, S. M. L., Yasmin, Bearcroft, P. W. P., Harish, S., Furlong, A., McEniery, C. M., Brown, J., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.601641 · Cited by 416
Fleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G., Tesser, J., Modafferi, D., Poulakos, J., & Sun, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10870 · Cited by 392
Cited by
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Cavalli, G., De Luca, G., Campochiaro, C., Della-Torre, E., Ripa, M., Canetti, D., Oltolini, C., Castiglioni, B., Tassan Din, C., Boffini, N., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30127-2 · Cited by 970
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases
Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klunker, S., Meyer, N., O’Mahony, L., Palomares, O., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.050 · Cited by 778
Murphy, S. P., Kakkar, R., McCarthy, C. P., & Januzzi, J. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.014 · Cited by 738
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Marchio, P., Guerra-Ojeda, S., Vila, J. M., Aldasoro, M., Victor, V. M., & Mauricio, M. D. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8563845 · Cited by 621
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Inflammatory cytokines in atherosclerosis: current therapeutic approaches
Tousoulis, D., Oikonomou, E., Economou, E. K., Crea, F., & Kaski, J. C. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv759 · Cited by 460
Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure
Hanna, A., & Frangogiannis, N. G. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07071-0 · Cited by 418
Abbate, A., Kontos, M. C., Grizzard, J. D., Biondi-Zoccai, G. G. L., Van Tassell, B. W., Robati, R., Roach, L. M., Arena, R. A., Roberts, C. S., Varma, A., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.059 · Cited by 415
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S., & Abbate, A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 411
Abbate, A., Van Tassell, B. W., Biondi-Zoccai, G., Kontos, M. C., Grizzard, J. D., Spillman, D. W., Oddi, C., Roberts, C. S., Melchior, R. D., Mueller, G. H., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.01.287 · Cited by 393
Cavalli, G., Colafrancesco, S., Emmi, G., Imazio, M., Lopalco, G., Maggio, M. C., Sota, J., & Dinarello, C. A. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102763 · Cited by 346
Immune Cell and Other Noncardiomyocyte Regulation of Cardiac Hypertrophy and Remodeling
Frieler, R. A., & Mortensen, R. M. (2015) · Circulation · doi:10.1161/circulationaha.114.008788 · Cited by 334
Cardiac fibrosis: new insights into the pathogenesis
Ma, Z.-G., Yuan, Y.-P., Wu, H.-M., Zhang, X., & Tang, Q.-Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.28103 · Cited by 331
Targeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
Coronary Microvascular Dysfunction
Vancheri, F., Longo, G., Vancheri, S., & Henein, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092880 · Cited by 321
Koenig, W. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.113 · Cited by 315
“In rheumatoid arthritis, the IL-1 RA anakinra is associated with reduced plasma levels of IL-6, hs-CRP, and the vasoconstrictor endothelin-1, aswell as improvement in coronaryflow reserve, LV function, and flow mediated brachial artery dilation [96].”
BackgroundThe role of IL-1 in the pathogenesis of heart disease
Bujak, M., & Frangogiannis, N. G. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0024-y · Cited by 307
Targeting Interleukin-1 in Heart Disease
Van Tassell, B. W., Toldo, S., Mezzaroma, E., & Abbate, A. (2013) · Circulation · doi:10.1161/circulationaha.113.003199 · Cited by 302
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
van Diepen, J. A., Berbée, J. F. P., Havekes, L. M., & Rensen, P. C. N. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.02.028 · Cited by 292
Van Tassell, B. W., Arena, R., Biondi-Zoccai, G., McNair Canada, J., Oddi, C., Abouzaki, N. A., Jahangiri, A., Falcao, R. A., Kontos, M. C., Shah, K. B., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.047 · Cited by 281
Management of Myocarditis-Related Cardiomyopathy in Adults
Tschöpe, C., Cooper, L. T., Torre-Amione, G., & Van Linthout, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313578 · Cited by 279
Averting inflammation by targeting the cytokine environment
Kopf, M., Bachmann, M. F., & Marsland, B. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2805 · Cited by 257
Vascular function and morphology in rheumatoid arthritis: a systematic review
Sandoo, A., Veldhuijzen van Zanten, J. J. C. S., Metsios, G. S., Carroll, D., & Kitas, G. D. (2011) · Rheumatology · doi:10.1093/rheumatology/ker275 · Cited by 146
Inflammation in Coronary Microvascular Dysfunction
Sagris, M., Theofilis, P., Antonopoulos, A. S., Oikonomou, E., Paschaliori, C., Galiatsatos, N., Tsioufis, K., & Tousoulis, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413471 · Cited by 115
Treating Life-Threatening Myocarditis by Blocking Interleukin-1*
Cavalli, G., Pappalardo, F., Mangieri, A., Dinarello, C. A., Dagna, L., & Tresoldi, M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001654 · Cited by 96
Myocarditis: An Interleukin-1-Mediated Disease?
De Luca, G., Cavalli, G., Campochiaro, C., Tresoldi, M., & Dagna, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01335 · Cited by 79
“(86) (2008) Rheumatoid arthritis (23) Double-blind, randomized cross-over trial.”
ResultInterleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure
Cavalli, G., Foppoli, M., Cabrini, L., Dinarello, C. A., Tresoldi, M., & Dagna, L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00131 · Cited by 70
“This observation is not unprecedented, as a single dose of anakinra increased cardiac contractility in patients with rheumatoid arthritis within hours of administration (30).”
Background
Metadata
- Authors
- Ikonomidis, I., Lekakis, J. P., Nikolaou, M., Paraskevaidis, I., Andreadou, I., Kaplanoglou, T., Katsimbri, P., Skarantavos, G., Soucacos, P. N., & Kremastinos, D. T.
- Venue
- Circulation
- Published
- 2008-05-20
- Volume
- 117
- Issue
- 20
- Pages
- 2662-2669
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2042227371
- Cited by
- 307
- References
- 35
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.